

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
16 November 2006 (16.11.2006)

PCT

(10) International Publication Number  
**WO 2006/121280 A1**

(51) International Patent Classification:  
**A61K 33/36** (2006.01) **A61P 13/00** (2006.01)

(21) International Application Number:  
PCT/KR2006/001731

(22) International Filing Date: 9 May 2006 (09.05.2006)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
05076071.9 9 May 2005 (09.05.2005) EP

(71) Applicant (for all designated States except US):  
**KOMIPHARM INTERNATIONAL CO., LTD.**  
[KR/KR]; 1 Ra-107 Shihwa Industrial Complex, Jung-  
wang-dong, Shihung, Kyonggi-do 429-944 (KR).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **LEE, Sang-Bong**  
[KR/KR]; 212-1103 Daelim Apt., Choweon Maul, Pyong-  
chon-dong, Anyang, Kyonggi-do 431-070 (KR). **YANG,**  
**Yong-Jin** [KR/KR]; 25404 Sk Town House, Kumi-dong,  
Bundang-gu, Seongnam, Kyonggi-do 463-500 (KR).

(74) Agent: **C & S PATENT AND LAW OFFICE**; C-2306  
Daelim Acrotel, 467-6 Dogok-dong, Kangnam-gu, Seoul  
135-971 (KR).

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,  
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,  
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,  
KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV,  
LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI,  
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG,  
SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US,  
UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, GH,  
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,  
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,  
FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT,  
RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA,  
GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**

— with international search report

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

(54) Title: PHARMACEUTICAL COMPOSITIONS COMPRISING OF ARSENOUS ACID, ITS SODIUM SALT AND ITS  
DERIVATIVES INTENDED FOR THE TREATMENT OF UROGENITAL CANCER AND ITS METASTASIS

(57) Abstract: The present application relates to pharmaceutical compositions and methods for treatment of urogenital diseases and bone metastasis in a human, which pharmaceutical composition contains an effective amount of arsenous acid alkaline or earth alkaline metal salt and/or a pharmaceutically acceptable adjuvant. According to the present invention, the alkaline arsenous acid metal salt is sodium meta-arsenite( $\text{AsO}_2\text{Na}$ ) or potassium meta-arsenite( $\text{AsO}_2\text{K}$ ). The effective amount of arsenous acid alkaline or earth alkaline metal salt is 0.0001-1500 mg/kg, preferably 1-1000 mg/kg, more preferably 1-150 mg/kg, and most preferably 50-100 mg/kg of body weight/day. The administration form of the pharmaceutical compositions of the invention is preferably oral, such as a tablet, capsule, powder and/or solution with a pharmaceutically acceptable carrier, diluent or excipient.

WO 2006/121280 A1